Quantum Biopharma (NASDAQ:QNTM – Get Free Report) and Veracyte (NASDAQ:VCYT – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
1.2% of Quantum Biopharma shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 1.6% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Quantum Biopharma has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quantum Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Veracyte | 1 | 3 | 6 | 1 | 2.64 |
Veracyte has a consensus price target of $54.33, indicating a potential upside of 15.06%. Given Veracyte’s stronger consensus rating and higher probable upside, analysts plainly believe Veracyte is more favorable than Quantum Biopharma.
Profitability
This table compares Quantum Biopharma and Veracyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum Biopharma | N/A | -941.54% | -224.41% |
| Veracyte | 20.37% | 9.26% | 8.61% |
Earnings and Valuation
This table compares Quantum Biopharma and Veracyte”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quantum Biopharma | N/A | N/A | -$26.17 million | ($8.25) | -0.42 |
| Veracyte | $517.15 million | 7.34 | $66.35 million | $1.41 | 33.49 |
Veracyte has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
Summary
Veracyte beats Quantum Biopharma on 12 of the 14 factors compared between the two stocks.
About Quantum Biopharma
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
About Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
